Australian respiratory medical device company Adherium (ASX:ADR) has announced a new strategic data-based initiative with Summatix.
Summatix is a private Melbourne-based medical informatics company developing a data platform to assist its clients in the dissemination and creation of medical data for clinicians.
Adherium said the new initiative, which builds on its existing relationship with Summatix, has the objective of enabling clinicians to enhance their care of patients with asthma and chronic obstructive pulmonary disease (COPD).
Under the initiative, Adherium will gain access to the regulated Summatix platform, enabling data generated from its connected Hailie sensors to be disseminated for clinical and other relevant use.
The Hailie sensors, formerly known as Smartinhalers, attach to a patient’s asthma or COPD medication inhaler to monitor dose compliance and promote a high level of adherence.
The Summatix digital platform allows connected external and implanted medical devices to be integrated, with the resulting data shared with patients, clinicians, payers (such as health insurers) and the connected device manufacturer.
Adherium said it will work with Summatix to develop a roadmap to accelerate the Hailie reimbursement focused rollout in the US, as well as in other key target markets including the UK, the European Union, China and Japan.
Adherium also announced the launch of its new Hailie patient-facing app and physician platform, which it said has been entirely revamped and strengthened. Enhancements include a cloud-first architecture and compliance with global privacy and interoperability standards.
“Adherium is excited to be partnering with Summatix in our continued efforts to deliver transformative asthma/COPD patient care,” said Adherium CEO Jeremy Curnock Cook.
“We are confident that when combined with the Summatix platform capabilities, Adherium’s Hailie™ solution will deliver significant advantages for patients, caregivers, doctors, and other health care providers in managing these costly diseases.”